u/SerialRealer

"Open-weight models lower adoption costs, expand developer communities and allow companies to work around constraints imposed by a lack of access to the most advanced chips. They are especially attractive to emerging markets but are gaining popularity among developers worldwide because of their cost efficiency and adaptability to different workloads.

Xi’s ambition is to accelerate the global proliferation of Chinese technology, build a stronger strategic foothold abroad, diversify China’s exposure to geopolitical risk and shape the global system more in China’s favour."

China’s open-source strategy is turning constraint into global reach. Countries adopting those models absorb Chinese technical standards over time. The more durable answer for the US is not only export controls, but a deliberate effort to develop strong open-weight models that can compete on performance, cost, and adoption.

Pretty reasonable balance. Open models stay freer to move, which feels healthier at this stage.

Closed model labs have spent a lot of time arguing that their systems are uniquely powerful and potentially dangerous. If that’s the case, it makes sense that they go through an extra review step. Leaving open models out keeps the broader ecosystem from getting bogged down too early. If closed models can’t stay meaningfully ahead, then treating them as special cases starts to look less justified anyway.

A Duchenne mom whose son is now 33 wrote this piece about why one-size-fits-all regulation doesn’t work for progressive rare diseases like DMD.

She argues that treatments need to be more flexible and tailored to different mutations and disease stages. The restricted access to Elevidys for non-ambulatory individuals is cited as one example of where current frameworks may leave patients without meaningful options.

Given how much NIH invests in rare disease and gene therapy research, curious what people here think about the current gap between scientific progress and regulatory flexibility.

DeepSeek founder Liang Wenfeng, speaking in a closed-door investor meeting in May 2026:

"If it were in a normal business environment where I could buy NVIDIA cards, then domestic substitution would be relatively hard; but when NVIDIA cards can’t be bought, everyone is forced into it, everyone has to do domestic chips."

Translation: Thanks for the export controls. Otherwise we’d still be buying American.

https://preview.redd.it/bdyetcjdjtfh1.png?width=1494&format=png&auto=webp&s=a4ebb020fc0fa015e0ffe983eeb8f52becc805a4

Open models spread capability, force better safety through real scrutiny, and stop a handful of labs from owning the future. Locked weights only protect the gatekeepers.

An 11-year-old boy from Türkiye is currently in treatment planning for Elevidys, the one-time gene therapy for Duchenne muscular dystrophy, at Burjeel Medical City in Abu Dhabi.

BMC is among the few centres in the UAE authorised to deliver this advanced therapy. The case is being managed by a multidisciplinary team including clinical genetics and cell & gene therapy specialists. The young patient has already tested negative for the relevant antibodies, making him eligible to proceed.

Rare disease care is becoming more reachable.

Closed US models at 50–100x the cost of Chinese open-weight models. Restricting the cheap option just handicaps US companies

https://preview.redd.it/8w6jxtjyafeh1.png?width=1060&format=png&auto=webp&s=e9f39bfe22786a938de5d244c94a7577b8f19e42

In mid-June, the Trump Administration imposed export controls on Anthropic’s most advanced models, Mythos 5 and Fable 5, requiring licenses for access by any foreign national, including the company’s own employees. The concerns were concrete: reports indicated guardrails could be jailbroken, enabling offensive capabilities, and there were questions about prior sharing with entities tied to China. Anthropic responded by disabling the models globally for all customers and dispatching staff to Washington to lobby. According to WIRED, White House officials had grown frustrated with CEO Dario Amodei, with one describing him as a “weirdo,” and began dealing instead with co-founder Tom Brown, finding the conversations more productive.

Meanwhile, China is advancing. Anthropic itself accused Chinese giant Alibaba of the largest known “distillation” attack on its systems. The campaign involved 28.8 million queries through roughly 25,000 fraudulent accounts and was designed to steal capabilities and accelerate Beijing’s progress.

Earlier in 2026, Anthropic sued the Trump Administration in multiple courts after being labeled a supply-chain risk, restricting its defense work. The company has hired multiple former Biden Administration officials into senior roles. Throughout American history, leading industries rallied behind the elected government during national challenges, such as building the Arsenal of Democracy in WW-II and the sophisticated weapons systems that won the Cold War. Defense contractors worked closely with the military; they did not sue it or frame security reviews as political attacks.

There is irony too. Anthropic long supported strict U.S. export controls on advanced chips to slow China. When similar national-security logic is applied to its own frontier models, the company treats it as overreach, responds with global shutdowns, and fights against it. A tightly controlled proprietary strategy is understandable from a business standpoint. But when it collides with domestic political disputes, the result is global blackouts of America’s most advanced AI tools. Adversaries can then steal the capabilities they need, as Anthropic itself has documented through distillation attacks, or surge ahead on their own while U.S. users and allies lose access.

DC is ramping up AI regulation. Banning open source would be a grave mistake